Thus, interfering with Furin activity-mediated Ca2+ mobilization and Orai and TRPC6 activation represent a potential strategy controlling malignant phenotype and resistance to therapy in triple negative breast cancer cells. The gene discussed is TRPC6; the disease is triple-negative breast carcinoma.